MA56462A - Inhibiteurs de hpk1 et leurs utilisations - Google Patents
Inhibiteurs de hpk1 et leurs utilisationsInfo
- Publication number
- MA56462A MA56462A MA056462A MA56462A MA56462A MA 56462 A MA56462 A MA 56462A MA 056462 A MA056462 A MA 056462A MA 56462 A MA56462 A MA 56462A MA 56462 A MA56462 A MA 56462A
- Authority
- MA
- Morocco
- Prior art keywords
- hpk1 inhibitors
- hpk1
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019094634 | 2019-07-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56462A true MA56462A (fr) | 2022-05-11 |
Family
ID=74100919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056462A MA56462A (fr) | 2019-07-04 | 2020-07-03 | Inhibiteurs de hpk1 et leurs utilisations |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20220389037A1 (fr) |
| EP (2) | EP3994133A4 (fr) |
| JP (2) | JP7633989B2 (fr) |
| KR (2) | KR20220044495A (fr) |
| CN (2) | CN114555585B (fr) |
| AU (2) | AU2020298649A1 (fr) |
| BR (1) | BR112022000064A2 (fr) |
| CA (1) | CA3145973A1 (fr) |
| DK (1) | DK4175951T3 (fr) |
| ES (1) | ES2981368T3 (fr) |
| FI (1) | FI4175951T3 (fr) |
| IL (1) | IL289612B2 (fr) |
| MA (1) | MA56462A (fr) |
| MX (2) | MX2022000271A (fr) |
| TW (1) | TWI878319B (fr) |
| WO (2) | WO2021000935A1 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| FI3873903T3 (fi) | 2018-10-31 | 2024-03-26 | Gilead Sciences Inc | Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| KR20220044495A (ko) * | 2019-07-04 | 2022-04-08 | 치루 레고르 테라퓨틱스 인코포레이티드 | Hpk1 억제제 및 그의 용도 |
| CN115279771B (zh) | 2020-01-15 | 2025-03-21 | 缆图药品公司 | Map4k1抑制剂 |
| CN116456985A (zh) * | 2020-09-23 | 2023-07-18 | 深圳市原力生命科学有限公司 | 作为hpk1调节剂的嘧啶及吡啶衍生物和其使用方法 |
| US20230399327A1 (en) * | 2020-10-28 | 2023-12-14 | Adlai Nortye Biopharma Co., Ltd. | High activity hpk1 kinase inhibitor |
| US12252488B2 (en) | 2021-02-12 | 2025-03-18 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| US11926625B2 (en) * | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| EP4305041A1 (fr) * | 2021-03-08 | 2024-01-17 | Blueprint Medicines Corporation | Inhibiteurs de map4k1 |
| CN117295748A (zh) * | 2021-03-08 | 2023-12-26 | 缆图药品公司 | Map4k1抑制剂 |
| TW202246263A (zh) * | 2021-03-23 | 2022-12-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | Ｈｐｋ１激酶抑制劑化合物 |
| JP2024513011A (ja) | 2021-03-29 | 2024-03-21 | ニンバス サターン， インコーポレイテッド | Ｈｐｋ１アンタゴニスト及びその使用 |
| CN117377673A (zh) * | 2021-03-29 | 2024-01-09 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| WO2022214008A1 (fr) * | 2021-04-08 | 2022-10-13 | 杭州阿诺生物医药科技有限公司 | Inhibiteur de la kinase hpk1 hautement actif |
| KR20240083168A (ko) * | 2021-07-14 | 2024-06-11 | 블루프린트 메디신즈 코포레이션 | Map4k1 저해제로서의 헤테로사이클 화합물 |
| EP4373817B1 (fr) | 2021-07-20 | 2025-05-21 | Astrazeneca AB | Pyrazine-2-carboxamides substituées utilisées en tant qu'inhibiteurs de hpk1 pour le traitement du cancer |
| WO2023083299A1 (fr) * | 2021-11-12 | 2023-05-19 | 微境生物医药科技(上海)有限公司 | Composé cyclique fusionné utilisé en tant qu'inhibiteur de hpk1 |
| CN118434729A (zh) * | 2022-01-11 | 2024-08-02 | 微境生物医药科技(上海)有限公司 | 作为hpk1抑制剂的稠环化合物 |
| WO2023245329A1 (fr) * | 2022-06-20 | 2023-12-28 | Biofront Ltd | Inhibiteurs de kinases multiples, compositions de ceux-ci et leurs procédés d'utilisation |
| CN116162087B (zh) * | 2023-02-20 | 2024-07-23 | 杭州医学院 | 一种hpk 1和/或lck激酶调节剂、制备方法及其应用 |
| CN116813692A (zh) * | 2023-06-29 | 2023-09-29 | 凌科药业(杭州)有限公司 | 含磷化合物、其药物组合物及其用途 |
| WO2025096647A1 (fr) * | 2023-10-30 | 2025-05-08 | Nimbus Saturn, Inc. | Méthodes de traitement de tumeurs |
| WO2025137168A2 (fr) | 2023-12-19 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Formes salines et solides d'un inhibiteur de hpk1 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007041511A2 (fr) | 2005-09-30 | 2007-04-12 | New York University | Kinase des progeniteurs hematopoietiques 1 destinee a la modulation d'une reponse immune |
| CA2654670A1 (fr) * | 2006-07-06 | 2008-01-10 | Boehringer Ingelheim International Gmbh | Nouveaux composes |
| AU2007336893A1 (en) * | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines for PDK1 inhibition |
| WO2008110508A1 (fr) * | 2007-03-09 | 2008-09-18 | Glaxo Group Limited | Composés |
| EP2226315A4 (fr) * | 2007-12-28 | 2012-01-25 | Carna Biosciences Inc | Dérivé de 2-aminoquinazoline |
| US20100121052A1 (en) * | 2008-06-20 | 2010-05-13 | Rama Jain | Novel compounds for treating proliferative diseases |
| WO2012135631A1 (fr) * | 2011-03-30 | 2012-10-04 | Arrien Pharmaeuticals Llc | 5-(pyrazin-2-yl)-1h-pyrazolo[3,4-b]pyridine substituée et dérivés de pyrazolo[3,4-b]pyridine en tant qu'inhibiteurs de protéine kinase |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| WO2015112441A1 (fr) * | 2014-01-22 | 2015-07-30 | Merck Sharp & Dohme Corp. | Inhibiteurs de métallo-bêta-lactamases |
| CN104876914B (zh) * | 2014-02-28 | 2017-04-19 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类间变性淋巴瘤激酶抑制剂 |
| CN106458914B (zh) * | 2014-03-28 | 2020-01-14 | 常州捷凯医药科技有限公司 | 作为axl抑制剂的杂环化合物 |
| CN106188029B (zh) * | 2015-05-05 | 2018-09-18 | 山东轩竹医药科技有限公司 | 二并环类间变性淋巴瘤激酶抑制剂 |
| ES2837157T3 (es) * | 2016-06-30 | 2021-06-29 | Janssen Pharmaceutica Nv | Derivados de cianoindolina como inhibidores de NIK |
| WO2018049214A1 (fr) * | 2016-09-09 | 2018-03-15 | Incyte Corporation | Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer |
| WO2018102366A1 (fr) * | 2016-11-30 | 2018-06-07 | Ariad Pharmaceuticals, Inc. | Anilinopyrimidines en tant qu'inhibiteurs de kinase 1 progénitrices hématopoïétiques (hpk1) |
| WO2018152220A1 (fr) * | 2017-02-15 | 2018-08-23 | Incyte Corporation | Composés de pyrazolopyridine et leurs utilisations |
| CN110402248B (zh) * | 2017-03-15 | 2023-01-06 | 豪夫迈·罗氏有限公司 | 作为hpk1抑制剂的氮杂吲哚类 |
| EP3694861A4 (fr) * | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | Composés hétérocycliques et leurs utilisations |
| US10745388B2 (en) * | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US10899755B2 (en) * | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| US20220242870A1 (en) * | 2019-05-17 | 2022-08-04 | Voronoi Inc. | Heterocycle-fused pyrimidine derivative and use thereof |
| KR20220044495A (ko) * | 2019-07-04 | 2022-04-08 | 치루 레고르 테라퓨틱스 인코포레이티드 | Hpk1 억제제 및 그의 용도 |
-
2020
- 2020-07-03 KR KR1020227003145A patent/KR20220044495A/ko active Pending
- 2020-07-03 BR BR112022000064A patent/BR112022000064A2/pt not_active Application Discontinuation
- 2020-07-03 WO PCT/CN2020/100134 patent/WO2021000935A1/fr not_active Ceased
- 2020-07-03 TW TW109122604A patent/TWI878319B/zh active
- 2020-07-03 US US17/624,514 patent/US20220389037A1/en active Pending
- 2020-07-03 JP JP2022500151A patent/JP7633989B2/ja active Active
- 2020-07-03 CN CN202080057904.1A patent/CN114555585B/zh active Active
- 2020-07-03 MX MX2022000271A patent/MX2022000271A/es unknown
- 2020-07-03 AU AU2020298649A patent/AU2020298649A1/en active Pending
- 2020-07-03 MA MA056462A patent/MA56462A/fr unknown
- 2020-07-03 CA CA3145973A patent/CA3145973A1/fr active Pending
- 2020-07-03 EP EP20834163.6A patent/EP3994133A4/fr active Pending
-
2021
- 2021-07-02 US US18/013,402 patent/US20230339896A1/en active Pending
- 2021-07-02 AU AU2021299849A patent/AU2021299849A1/en active Pending
- 2021-07-02 JP JP2023500011A patent/JP7759374B2/ja active Active
- 2021-07-02 ES ES21742686T patent/ES2981368T3/es active Active
- 2021-07-02 CN CN202180053862.9A patent/CN116096370B/zh active Active
- 2021-07-02 EP EP21742686.5A patent/EP4175951B1/fr active Active
- 2021-07-02 KR KR1020237003551A patent/KR20230035061A/ko active Pending
- 2021-07-02 MX MX2023000025A patent/MX2023000025A/es unknown
- 2021-07-02 FI FIEP21742686.5T patent/FI4175951T3/fi active
- 2021-07-02 DK DK21742686.5T patent/DK4175951T3/da active
- 2021-07-02 WO PCT/CN2021/104206 patent/WO2022002237A1/fr not_active Ceased
-
2022
- 2022-01-04 IL IL289612A patent/IL289612B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114555585A (zh) | 2022-05-27 |
| ES2981368T3 (es) | 2024-10-08 |
| US20230339896A1 (en) | 2023-10-26 |
| IL289612B1 (en) | 2025-10-01 |
| MX2022000271A (es) | 2022-04-20 |
| JP7759374B2 (ja) | 2025-10-23 |
| TWI878319B (zh) | 2025-04-01 |
| CA3145973A1 (fr) | 2021-01-07 |
| BR112022000064A2 (pt) | 2022-05-24 |
| IL289612B2 (en) | 2026-02-01 |
| CN114555585B (zh) | 2025-02-11 |
| KR20230035061A (ko) | 2023-03-10 |
| US20220389037A1 (en) | 2022-12-08 |
| KR20220044495A (ko) | 2022-04-08 |
| MX2023000025A (es) | 2023-04-04 |
| WO2021000935A1 (fr) | 2021-01-07 |
| EP3994133A4 (fr) | 2023-11-22 |
| AU2021299849A1 (en) | 2023-02-23 |
| FI4175951T3 (fi) | 2024-07-10 |
| JP7633989B2 (ja) | 2025-02-20 |
| CN116096370A (zh) | 2023-05-09 |
| TW202116751A (zh) | 2021-05-01 |
| CN116096370B (zh) | 2024-12-20 |
| JP2023533938A (ja) | 2023-08-07 |
| EP4175951B1 (fr) | 2024-05-01 |
| EP3994133A1 (fr) | 2022-05-11 |
| WO2022002237A1 (fr) | 2022-01-06 |
| AU2020298649A1 (en) | 2022-02-17 |
| IL289612A (en) | 2022-03-01 |
| DK4175951T3 (da) | 2024-07-29 |
| JP2022538923A (ja) | 2022-09-06 |
| EP4175951A1 (fr) | 2023-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56462A (fr) | Inhibiteurs de hpk1 et leurs utilisations | |
| EP3972978A4 (fr) | Inhibiteurs de kras g12c et leurs utilisations | |
| EP3870579A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| EP3746075A4 (fr) | Inhibiteurs de gcn2 et leurs utilisations | |
| EP3768664A4 (fr) | Inhibiteurs de shp2 et leurs utilisations | |
| EP4232425A4 (fr) | Inhibiteurs de ctps1 et leurs utilisations | |
| EP3866789A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| EP3946360A4 (fr) | Agents de dégradation de stat et leurs utilisations | |
| EP3886843A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| EP3600273A4 (fr) | Inhibiteurs de cd73 et leurs utilisations | |
| EP3938369A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| EP3810182A4 (fr) | Néoantigènes et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP4093768A4 (fr) | Constructions cal-t et leurs utilisations | |
| EP3471727A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3624797A4 (fr) | Inhibiteurs de kinase et leurs utilisations | |
| EP3914357A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
| EP3389658A4 (fr) | Inhibiteurs de glycosidase et leurs utilisations | |
| EP3860636A4 (fr) | Inhibiteurs de matriptase 2 et leurs utilisations | |
| EP3902530A4 (fr) | Nanovaccins polymères et leurs utilisations | |
| EP3870162A4 (fr) | Inhibiteurs de ssao et leurs utilisations | |
| EP3471726A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP4291235A4 (fr) | Antagonistes de hpk1 et leurs utilisations | |
| EP3976009A4 (fr) | Inhibiteurs de bax et leurs utilisations | |
| EP4041236A4 (fr) | Inhibiteurs de kinase tricycliques et leurs utilisations |